Obesity-related hypertension: Epidemiology, pathophysiology, treatments, and the contribution of perivascular adipose tissue

References

• WHO. Obesity and Overweight: Fact Sheet number 311. 2011 [updated 2011; cited]; Available from: http://www.who.int/mediacentre/factsheets/fs311/en/index.html (accessed 8 November 2009).
   Google Scholar
• The NHS Information Centre LS. Statistics on obesity, physical activity and diet: England, 2011. Available from: http://www.ic.nhs.uk/pubs/opad11. Publisher: The health and social care information centre. (accessed 24 February 2011).
   Google Scholar
• CDC. U.S. Obesity Trends. 2011 [updated 2011; cited 18 August 2011]. Available from: http://www.cdc.gov/obesity/data/trends.html#State.
   Google Scholar
• ; Emerging Risk Factors CollaborationWormser D, Kaptoge S, Di Angelantonio E, Wood AM, Pennells L, . Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies. Lancet. 2011;377: 1085–95.
   PubMed Web of Science ®Google Scholar
• Cornier MA, Despres JP, Davis N, Grossniklaus DA, Klein S, Lamarche B, . Assessing adiposity: a scientific statement from the American Heart Association. Circulation. 2011;124:1996–2019.
   PubMed Web of Science ®Google Scholar
• CDC. Hypertension. 2011 [updated 2011; cited 18 August 2011]. Available from: http://www.cdc.gov/nchs/fastats/hyprtens.htm.
   Google Scholar
• WHO. Blood pressure. 2011 [updated 2011; cited 17 July 2011]. Available from: http://www.who.int/gho/ncd/risk_factors/blood_pressure_prevalence/en/index.html.
   Google Scholar
• Henry SL, Barzel B, Wood-Bradley RJ, Burke SL, Head GA, Armitage JA. The developmental origins of obesity-related hypertension. ClinExpPharmacol Physiol. 2011 Aug 1. [Epub ahead of print].
   Google Scholar
• Kotchen TA. Obesity-related hypertension: epidemiology, pathophysiology, and clinical management. Am J Hypertens. 2010;23:1170–8.
   PubMed Web of Science ®Google Scholar
• Gosmanov AR, Smiley DD, Robalino G, Siquiera J, Khan B, Le NA, . Effects of oral and intravenous fat load on blood pressure, endothelial function, sympathetic activity, and oxidative stress in obese healthy subjects. Am J Physiol Endocrinol Metab. 2010;299:E953–8.
   Web of Science ®Google Scholar
• Dobrian AD, Schriver SD, Lynch T, Prewitt RL. Effect of salt on hypertension and oxidative stress in a rat model of diet-induced obesity. Am J Physiol Renal Physiol. 2003;285: F619–28.
   PubMed Web of Science ®Google Scholar
• Hall JE, da Silva AA, do Carmo JM, Dubinion J, Hamza S, Munusamy S, . Obesity-induced hypertension: role of sympathetic nervous system, leptin, and melanocortins. J Biol Chem. 2010;285:17271–6.
   PubMed Web of Science ®Google Scholar
• Hall JE, Brands MW, Henegar JR. Mechanisms of hypertension and kidney disease in obesity. Ann N Y Acad Sci. 1999;892:91–107.
   PubMed Web of Science ®Google Scholar
• Rumantir MS, Vaz M, Jennings GL, Collier G, Kaye DM, Seals DR, . Neural mechanisms in human obesity-related hypertension. J Hypertens. 1999;17:1125–33.
   PubMed Web of Science ®Google Scholar
• Esler M, Straznicky N, Eikelis N, Masuo K, Lambert G, Lambert E. Mechanisms of sympathetic activation in obesity-related hypertension. Hypertension. 2006;48:787–96.
   PubMed Web of Science ®Google Scholar
• Nagae A, Fujita M, Kawarazaki H, Matsui H, Ando K, Fujita T. Sympathoexcitation by oxidative stress in the brain mediates arterial pressure elevation in obesity-induced hypertension. Circulation. 2009;119:978–86.
   PubMed Web of Science ®Google Scholar
• Van Harmelen V, Ariapart P, Hoffstedt J, Lundkvist I, Bringman S, Arner P. Increased adipose angiotensinogen gene expression in human obesity. Obesity. 2000;8:337–41.
   Web of Science ®Google Scholar
• Engeli S, Negrel R, Sharma AM. Physiology and pathophysiology of the adipose tissue renin-angiotensin system. Hypertension. 2000;35:1270–7.
   PubMed Web of Science ®Google Scholar
• Goodfriend TL, Calhoun DA. Resistant hypertension, obesity, sleep apnea, and aldosterone: theory and therapy. Hypertension. 2004;43:518–24.
   PubMed Web of Science ®Google Scholar
• Goodfriend TL, Egan BM, Kelley DE. Aldosterone in obesity. Endocr Res. 1998;24:789–96.
   PubMed Web of Science ®Google Scholar
• Goodfriend TL, Kelley DE, Goodpaster BH, Winters SJ. Visceral obesity and insulin resistance are associated with plasma aldosterone levels in women. Obes Res. 1999;7: 355–62.
   PubMedGoogle Scholar
• Maron BA, Zhang YY, Handy DE, Beuve A, Tang SS, Loscalzo J, . Aldosterone increases oxidant stress to impair guanylyl cyclase activity by cysteinylthiol oxidation in vascular smooth muscle cells. J Biol Chem. 2009;284: 7665–72.
   PubMed Web of Science ®Google Scholar
• Wang H, Shimosawa T, Matsui H, Kaneko T, Ogura S, Uetake Y, . Paradoxical mineralocorticoid receptor activation and left ventricular diastolic dysfunction under high oxidative stress conditions. J Hypertens. 2008;26: 1453–62.
   PubMed Web of Science ®Google Scholar
• Leopold JA, Dam A, Maron BA, Scribner AW, Liao R, Handy DE, . Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity. Nat Med. 2007;13:189–97.
   PubMed Web of Science ®Google Scholar
• Maron BA, Leopold JA. Aldosterone receptor antagonists: effective but often forgotten. Circulation. 2010;121: 934–9.
   PubMed Web of Science ®Google Scholar
• de Paula RB, da Silva AA, Hall JE. Aldosterone antagonism attenuates obesity-induced hypertension and glomerular hyperfiltration. Hypertension. 2004;43:41–7.
   PubMed Web of Science ®Google Scholar
• Rahmouni K, Barthelmebs M, Grima M, Imbs JL, De Jong W. Involvement of brain mineralocorticoid receptor in salt-enhanced hypertension in spontaneously hypertensive rats. Hypertension. 2001;38:902–6.
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Cooke CR, Andres R, Faloona GR, Davis PJ. The effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man. J Clin Invest. 1975;55: 845–55.
   PubMed Web of Science ®Google Scholar
• Kotsis V, Stabouli S, Papakatsika S, Rizos Z, Parati G. Mechanisms of obesity-induced hypertension. Hypertens Res. 2010;33:386–93.
   PubMed Web of Science ®Google Scholar
• Zheng Y, Yamada H, Sakamoto K, Horita S, Kunimi M, Endo Y, . Roles of insulin receptor substrates in insulin-induced stimulation of renal proximal bicarbonate absorption. J Am SocNephrol. 2005;16:2288–95.
   Web of Science ®Google Scholar
• Safar ME, Czernichow S, Blacher J. Obesity, arterial stiffness, and cardiovascular risk. J Am SocNephrol. 2006;17 (Suppl 2):S109–11.
   Google Scholar
• Singhal A, Farooqi IS, Cole TJ, O'Rahilly S, Fewtrell M, Kattenhorn M, . Influence of leptin on arterial distensibility: a novel link between obesity and cardiovascular disease? Circulation. 2002;106:1919–24.
   PubMed Web of Science ®Google Scholar
• Westerbacka J, Vehkavaara S, Bergholm R, Wilkinson I, Cockcroft J, Yki-Jarvinen H. Marked resistance of the ability of insulin to decrease arterial stiffness characterizes human obesity. Diabetes. 1999;48:821–7.
   PubMed Web of Science ®Google Scholar
• Yudkin JS, Eringa E, Stehouwer CD. “Vasocrine” signalling from perivascular fat: a mechanism linking insulin resistance to vascular disease. Lancet. 2005;365:1817–20.
   PubMed Web of Science ®Google Scholar
• Jin RC, Loscalzo J. Vascular nitric oxide: formation and function. J Blood Med. 2010;2010:147–62.
   PubMedGoogle Scholar
• Peppard PE, Young T, Palta M, Skatrud J. Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med. 2000;342:1378–84.
   PubMed Web of Science ®Google Scholar
• Wolk R, Shamsuzzaman AS, Somers VK. Obesity, sleep apnea, and hypertension. Hypertension. 2003;42:1067–74.
   PubMed Web of Science ®Google Scholar
• Yang R, Sikka G, Larson J, Watts VL, Niu X, Ellis CL, . Restoring leptin signaling reduces hyperlipidemia and improves vascular stiffness induced by chronic intermittent hypoxia. Am J Physiol Heart Circ Physiol. 2011;300: H1467–76.
   Web of Science ®Google Scholar
• Dudenbostel T, Calhoun DA. Resistant hypertension, obstructive sleep apnoea and aldosterone. J Hum Hypertens. 2010 Jun 9. [Epub ahead of print].
   Web of Science ®Google Scholar
• Soltis EE, Cassis LA. Influence of perivascular adipose tissue on rat aortic smooth muscle responsiveness. ClinExpHypertens A. 1991;13:277–96.
   Google Scholar
• Gao YJ, Lu C, Su LY, Sharma AM, Lee RM. Modulation of vascular function by perivascular adipose tissue: the role of endothelium and hydrogen peroxide. Br J Pharmacol. 2007;151:323–31.
   PubMed Web of Science ®Google Scholar
• Galvez-Prieto B, Bolbrinker J, Stucchi P, de Las Heras AI, Merino B, Arribas S, . Comparative expression analysis of the renin-angiotensin system components between white and brown perivascular adipose tissue. J Endocrinol. 2008;197:55–64.
   PubMed Web of Science ®Google Scholar
• Lu C, Su LY, Lee RM, Gao YJ. Alterations in perivascular adipose tissue structure and function in hypertension. Eur J Pharmacol. 2011;656:68–73.
   PubMed Web of Science ®Google Scholar
• Dubrovska G, Verlohren S, Luft FC, Gollasch M. Mechanisms of ADRF release from rat aortic adventitial adipose tissue. Am J Physiol Heart Circ Physiol. 2004;286: H1107–13.
   PubMed Web of Science ®Google Scholar
• Deng G, Long Y, Yu YR, Li MR. Adiponectin directly improves endothelial dysfunction in obese rats through the AMPK-eNOS Pathway. Int J Obes (Lond). 2010;34:165–71.
   PubMed Web of Science ®Google Scholar
• Yilmaz MI, Sonmez A, Caglar K, Celik T, Yenicesu M, Eyileten T, . Effect of antihypertensive agents on plasma adiponectin levels in hypertensive patients with metabolic syndrome. Nephrology (Carlton). 2007;12:147–53.
   PubMed Web of Science ®Google Scholar
• Fesus G, Dubrovska G, Gorzelniak K, Kluge R, Huang Y, Luft FC, . Adiponectin is a novel humoral vasodilator. Cardiovasc Res. 2007;75:719–27.
   PubMed Web of Science ®Google Scholar
• Greenstein AS, Khavandi K, Withers SB, Sonoyama K, Clancy O, Jeziorska M, . Local inflammation and hypoxia abolish the protective anticontractile properties of perivascular fat in obese patients. Circulation. 2009;119: 1661–70.
   PubMed Web of Science ®Google Scholar
• Aghamohammadzadeh R, Withers SB, Lynch FM, Greenstein AS, Malik R, Heagerty AM. Perivascular adipose tissue from human systemic and coronary vessels: the emergence of a new pharmacotherapeutic target. Br J Pharmacol. 2012;165:670–82.
   PubMed Web of Science ®Google Scholar
• Lu C, Zhao AX, GaoYJ, Lee RM. Modulation of vein function by perivascular adipose tissue. Eur J Pharmacol. 2011;657:111–6.
   PubMed Web of Science ®Google Scholar
• Lee RM, Bader M, Alenina N, Santos RA, Gao YJ, Lu C. Mas receptors in modulating relaxation induced by perivascular adipose tissue. Life Sci. 2011;89:467–72.
   PubMed Web of Science ®Google Scholar
• Byku M, Macarthur H, Westfall TC. Inhibitory effects of angiotensin (1 - 7) on the nerve stimulation-induced release of norepinephrine and neuropeptide Y from the mesenteric arterial bed. Am J Physiol Heart Circ Physiol. 2010;298: H457–65.
   Web of Science ®Google Scholar
• Marques FD, Ferreira AJ, Sinisterra RD, Jacoby BA, Sousa FB, Caliari MV, . An oral formulation of angiotensin- (1 – 7) produces cardioprotective effects in infarcted and isoproterenol-treated rats. Hypertension. 2011;57:477–83.
   PubMed Web of Science ®Google Scholar
• Ribiere C, Jaubert AM, Gaudiot N, Sabourault D, Marcus ML, Boucher JL, . White adipose tissue nitric oxide synthase: a potential source for NO production. BiochemBiophys Res Commun. 1996;222:706–12.
   PubMed Web of Science ®Google Scholar
• Gil-Ortega M, Stucchi P, Guzman-Ruiz R, Cano V, Arribas S, Gonzalez MC, . Adaptativenitric oxide overproduction in perivascular adipose tissue during early diet-induced obesity. Endocrinology. 2010;151:3299–306.
   PubMed Web of Science ®Google Scholar
• Ribiere C, Jaubert AM, Sabourault D, Lacasa D, Giudicelli Y. Insulin stimulates nitric oxide production in rat adipocytes. BiochemBiophys Res Commun. 2002;291:394–9.
   PubMed Web of Science ®Google Scholar
• Mehebik N, Jaubert AM, Sabourault D, Giudicelli Y, Ribiere C. Leptin-induced nitric oxide production in white adipocytes is mediated through PKA and MAP kinase activation. Am J Physiol Cell Physiol. 2005;289:C379–87.
   Web of Science ®Google Scholar
• Rahmouni K, Correia ML, Haynes WG, Mark AL. Obesity-associated hypertension: new insights into mechanisms. Hypertension. 2005;45:9–14.
   PubMed Web of Science ®Google Scholar
• Mark AL, Shaffer RA, Correia ML, Morgan DA, Sigmund CD, Haynes WG. Contrasting blood pressure effects of obesity in leptin-deficient ob/ob mice and agouti yellow obese mice. J Hypertens. 1999;17(Pt 2):1949–53.
   PubMed Web of Science ®Google Scholar
• da Silva AA, do Carmo J, Dubinion J, Hall JE. The role of the sympathetic nervous system in obesity-related hypertension. CurrHypertens Rep. 2009;11:206–11.
   PubMed Web of Science ®Google Scholar
• Schleifenbaum J, Kohn C, Voblova N, Dubrovska G, Zavarirskaya O, Gloe T, . Systemic peripheral artery relaxation by KCNQ channel openers and hydrogen sulfide. J Hypertens. 2010;28:1875–82.
   PubMed Web of Science ®Google Scholar
• Lee YC, Chang HH, Chiang CL, Liu CH, Yeh JI, Chen MF, . Role of perivascular adipose tissue-derived methyl palmitate in vascular tone regulation and pathogenesis of hypertension. Circulation. 2011;124:1160–71.
   PubMed Web of Science ®Google Scholar
• Withers BS, Agabiti-Rosei C, Linvingstone DM, Little MC, Aslam R, Malik RA, . Macrophage activation is responsible for loss f anticontractile function in inflamed perivascular fat. ArteriosclerThrombVasc Biol. 2011;31: 908–13.
   PubMed Web of Science ®Google Scholar
• Fitzgibbons TP, Kogan S, Aouadi M, Hendricks GM, Straubhaar J, Czech MP. Similarity of mouse perivascular and brown adipose tissues and their resistance to diet-induced inflammation. Am J Physiol Heart Circ Physiol. 2011;301: H1425–37.
   PubMed Web of Science ®Google Scholar
• Guo C, Ricchiuti V, Lian BQ, Yao TM, Coutinho P, Romero JR, . Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-gamma, and proinflammatory adipokines. Circulation. 2008;117: 2253–61.
   PubMed Web of Science ®Google Scholar
• Gao YJ, Takemori K, Su LY, An WS, Lu C, Sharma AM, . Perivascular adipose tissue promotes vasoconstriction: the role of superoxide anion. Cardiovasc Res. 2006;71: 363–73.
   PubMed Web of Science ®Google Scholar
• Lu C, Su LY, Lee RM, Gao YJ. Mechanisms for perivascular adipose tissue-mediated potentiation of vascular contraction to perivascular neuronal stimulation: the role of adipocyte-derived angiotensin II. Eur J Pharmacol. 2011; 634:107–12.
   Web of Science ®Google Scholar
• Kanda H, Tateya S, Tamori Y, Kotani K, Hiasa K, Kitazawa R, . MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest. 2006;116:1494–505.
   PubMed Web of Science ®Google Scholar
• Kim CS, Park HS, Kawada T, Kim JH, Lim D, Hubbard NE, . Circulating levels of MCP-1 and IL-8 are elevated in human obese subjects and associated with obesity-related parameters. Int J Obes. 2006;30:1347–55.
   PubMed Web of Science ®Google Scholar
• Sartipy P, Loskutoff DJ. Monocyte chemoattractant protein 1 in obesity and insulin resistance. ProcNatlAcadSci USA. 2003;100:7265–70.
   PubMed Web of Science ®Google Scholar
• Shah R, Hinkle CC, Ferguson JF, Mehta NN, Li M, Qu L, . Fractalkine is a novel human adipochemokine associated with type 2 diabetes. Diabetes. 2011;60:1512–8.
   Google Scholar
• Sirois-Gagnon D, Chamberland A, Perron S, Brisson D, Gaudet D, Laprise C. Association of common polymorphisms in the fractalkine receptor (CX3CR1) with obesity. Obesity (Silver Spring). 2010;19:222–7.
   PubMed Web of Science ®Google Scholar
• Timofeeva AV, Goryunova LE, Khaspekov GL, Kovalevskii DA, Scamrov AV, Bulkina OS, . Altered gene expression pattern in peripheral blood leukocytes from patients with arterial hypertension. Ann N Y Acad Sci. 2006;1091: 319–35.
   PubMed Web of Science ®Google Scholar
• Chatterjee TK, Stoll LL, Denning GM, Harrelson A, Blomkalns AL, Idelman G, . Proinflammatory phenotype of perivascular adipocytes: influence of high-fat feeding. Circ Res. 2009;104:541–9.
   PubMed Web of Science ®Google Scholar
• Dorresteijn JA, Visseren FL, Spiering W. Mechanisms linking obesity to hypertension. Obes Rev. 2012;13:17–26.
   PubMed Web of Science ®Google Scholar
• Lee CM, Huxley RR, Wildman RP, Woodward M. Indices of abdominal obesity are better discriminators of cardiovascular risk factors than BMI: a meta-analysis. J ClinEpidemiol. 2008;61:646–53.
   Web of Science ®Google Scholar
• Reisin E, Abel R, Modan M, Silverberg DS, Eliahou HE, Modan B. Effect of weight loss without salt restriction on the reduction of blood pressure in overweight hypertensive patients. N Engl J Med. 1978;298:1–6.
   PubMed Web of Science ®Google Scholar
• Ahmadi N, Eshaghian S, Huizenga R, Sosnin K, Ebrahimi R, Siegel R. Effects of intense exercise and moderate caloric restriction on cardiovascular risk factors and inflammation. Am J Med. 2011;124:978–82.
   PubMed Web of Science ®Google Scholar
• Blumenthal JA, Sherwood A, Gullette ECD, Babyak M, Waugh R, Georgiades A, . Exercise and weight loss reduce blood pressure in men and women with mild hypertension: effects on cardiovascular, metabolic, and hemodynamic functioning. Arch Intern Med. 2000;160:1947–58.
   PubMed Web of Science ®Google Scholar
• Heneghan HM, Meron-Eldar S, Brethauer SA, Schauer PR, Young JB. Effect of bariatric surgery on cardiovascular risk profile. Am J Cardiol. 2011;108:1499–507.
   PubMed Web of Science ®Google Scholar
• Nicholas C, May R. HealthGrades Fifth Annual Bariatric Surgery Trends in American Hospitals Study; 2010 Contract No.: Document Number. Available from: http://www.healthgrades.com/media/DMS/pdf/HealthGradesBariatricSurgeryTrendsStudy2010.pdf. Publisher: HealthGrades Inc. (accessed 8 September 2010).
   Google Scholar
• Hofso D, Nordstrand N, Johnson LK, Karlsen TI, Hager H, Jenssen T, . Obesity-related cardiovascular risk factors after weight loss: a clinical trial comparing gastric bypass surgery and intensive lifestyle intervention. Eur J Endocrinol. 2010;163:735–45.
   PubMed Web of Science ®Google Scholar
• Frezza EE, Wei C, Wachtel MS. Is surgery the next answer to treat obesity-related hypertension? J ClinHypertens (Greenwich). 2009;11:284–8.
   PubMed Web of Science ®Google Scholar
• Butner KL, Nickols-Richardson SM, Clark SF, Ramp WK, Herbert WG. A review of weight loss following Roux-en-Y gastric bypass vs restrictive bariatric surgery: impact on adiponectin and insulin. Obes Surg.2010;20:559–68.
   PubMed Web of Science ®Google Scholar
• Compher C, Badellino KO. Obesity and inflammation: lessons from bariatric surgery. JPEN J Parenter Enteral Nutr. 2008;32:645–7.
   PubMed Web of Science ®Google Scholar
• Ibrahim MM. Subcutaneous and visceral adipose tissue: structural and functional differences. Obes Rev. 2009;11:11–18.
   PubMed Web of Science ®Google Scholar
• Forsythe LK, Wallace JM, Livingstone MB. Obesity and inflammation: the effects of weight loss. Nutr Res Rev. 2008;21:117–33.
   PubMed Web of Science ®Google Scholar
• Moschen AR, Molnar C, Geiger S, Graziadei I, Ebenbichler CF, Weiss H, . Anti-inflammatory effects of excessive weight loss: potent suppression of adipose interleukin 6 and tumour necrosis factor {alpha} expression. Gut.2010;59: 1259–64.
   PubMed Web of Science ®Google Scholar
• Blackburn GL, Wollner SB, Jones DB. Bariatric surgery as treatment for type 2 diabetes. CurrDiab Rep. 2010;10: 261–3.
   Google Scholar
• Kassab S, Kato T, Wilkins FC, Chen R, Hall JE, Granger JP. Renal denervation attenuates the sodium retention and hypertension associated with obesity. Hypertension. 1995;25(Pt 2):893–7.
   PubMed Web of Science ®Google Scholar
• ; SymplicityHTN-2 InvestigatorsEsler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, . Renal sympathetic denervation in patients with treatment-resistant hypertension (The SymplicityHTN-2 Trial): a randomised controlled trial. Lancet. 2010;376:1903–9.
   PubMed Web of Science ®Google Scholar
• The 1st renal denervation procedure to control hypertension conducted in the private sector. The Harley Street Clinic; 2010 [updated 2010; cited]. Available from: http://www.theharleystreetclinic.com/news/the-1st-renal-denervation-procedure-to-control-hypertension-conducted-in-the-private-sector (accessed 20 November 2011).
   Google Scholar
• Vaziri ND, Ni Z, Oveisi F, Trnavsky-Hobbs DL. Effect of antioxidant therapy on blood pressure and NO synthase expression in hypertensive rats. Hypertension. 2000;36: 957–64.
   PubMed Web of Science ®Google Scholar
• Drummond GR, Selemidis S, Griendling KK, Sobey CG. Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets. Nat Rev Drug Discov. 2011;10:453–71.
   PubMed Web of Science ®Google Scholar
• Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest. 2002;110: 229–38.
   PubMed Web of Science ®Google Scholar
• Wong KE, Szeto FL, Zhang W, Ye H, Kong J, Zhang Z, . Involvement of the vitamin D receptor in energy metabolism: regulation of uncoupling proteins. Am J PhysiolEndocrinolMetab. 2009;296:E820–8.
   PubMed Web of Science ®Google Scholar
• Wong KE, Kong J, Zhang W, Szeto FL, Ye H, Deb DK, . Targeted expression of human vitamin D receptor in adipocytes decreases energy expenditure and induces obesity in mice. J Biol Chem. 2011;286:33804–10.
   PubMed Web of Science ®Google Scholar
• Wortsman J, Matsuoka LY, Chen TC, Lu Z, Holick MF. Decreased bioavailability of vitamin D in obesity. Am J ClinNutr. 2000;72:690–3.
   PubMed Web of Science ®Google Scholar